Profits and share price down as AstraZeneca announces fourth quarter and 2014 results
Anglo-Swedish drug major AstraZeneca (LSE: AZN) met its upgraded guidance for 2014, though both profits and share price were down upon the announcement of its annual and quarterly financials. The firm's shares were down 2.6% to £45.67 in early afternoon trading.
Pascal Soriot, chief executive of AstraZeneca, accounted for this by saying there was “no surprise upside, no surprise downside,” and that his company had “done exactly what we said we would do.”
Quarterly sales stood at $6.68 billion, a slight decrease from the quarter in 2013, when sales were $6.84 billion. Full-year figures showed revenue of $26.1 billion, a 1% increase on 2013, when sales were $25.71 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze